16126736

Source:http://linkedlifedata.com/resource/pubmed/id/16126736

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0139121, umls-concept:C0144576, umls-concept:C0242640, umls-concept:C0717726, umls-concept:C0753474, umls-concept:C0920321, umls-concept:C1999216
pubmed:issue	12
pubmed:dateCreated	2005-11-24
pubmed:abstractText	The aim of this study was to determine (i) the maximum tolerated dose (MTD) of liposomal doxorubicin (L-DOX) and paclitaxel (DP), (ii) the MTD of DP plus valspodar (DPV) and (iii) pharmacokinetic (PK) interactions of valspodar with L-DOX and paclitaxel.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/M01 RR 00070, http://linkedlifedata.com/resource/pubmed/grant/R01 CA 52168
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporins, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Liposomes, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/valspodar
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0923-7534
pubmed:author	pubmed-author:AdvaniRR, pubmed-author:ChinD LDL, pubmed-author:FisherG AGA, pubmed-author:HalseyJJ, pubmed-author:JacobsC DCD, pubmed-author:KunA MAM, pubmed-author:SikicB IBI
pubmed:issnType	Print
pubmed:volume	16
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1968-73
pubmed:dateRevised	2007-11-14
pubmed:meshHeading	pubmed-meshheading:16126736-Adult, pubmed-meshheading:16126736-Aged, pubmed-meshheading:16126736-Aged, 80 and over, pubmed-meshheading:16126736-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16126736-Cohort Studies, pubmed-meshheading:16126736-Cyclosporins, pubmed-meshheading:16126736-Dose-Response Relationship, Drug, pubmed-meshheading:16126736-Doxorubicin, pubmed-meshheading:16126736-Drug Interactions, pubmed-meshheading:16126736-Drug Resistance, Multiple, pubmed-meshheading:16126736-Drug Resistance, Neoplasm, pubmed-meshheading:16126736-Female, pubmed-meshheading:16126736-Humans, pubmed-meshheading:16126736-Liposomes, pubmed-meshheading:16126736-Male, pubmed-meshheading:16126736-Maximum Tolerated Dose, pubmed-meshheading:16126736-Middle Aged, pubmed-meshheading:16126736-Neoplasm Staging, pubmed-meshheading:16126736-Neoplasms, pubmed-meshheading:16126736-Paclitaxel
pubmed:year	2005
pubmed:articleTitle	A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
pubmed:affiliation	Oncology Division, Stanford University Medical Center, Stanford, CA 94305-5151, USA.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I, Research Support, N.I.H., Extramural